2022
DOI: 10.1177/09612033221106301
|View full text |Cite
|
Sign up to set email alerts
|

Kidney thrombotic microangiopathy in lupus nephritis: Impact on treatment and prognosis

Abstract: Introduction Lupus nephritis (LN) may present with thrombotic microangiopathy (TMA) on kidney biopsy, the impact of which on outcomes is unclear. This study examined the prognostic importance of LN with TMA on kidney biopsy, including response to therapy and long-term outcomes. Methods We conducted a single-center, retrospective study of all cases of LN with concomitant TMA on kidney biopsy in the Glomerular Disease Collaborative Network database. Controls were individuals with LN without TMA matched to cases … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

1
1
0

Year Published

2022
2022
2025
2025

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 29 publications
1
1
0
Order By: Relevance
“…The case described had higher activity and chronicity indices and a stormy renal picture at presentation, a finding similar to studies done by Song et al and Azarniouch et al [9,11]. This highlights the fact that the overlooked vascular compartment in both ISN/RPS grading systems for categorization of LN into various classes and activity and chronicity indices needs further modifications to include VL.…”
Section: Discussionsupporting
confidence: 85%
“…The case described had higher activity and chronicity indices and a stormy renal picture at presentation, a finding similar to studies done by Song et al and Azarniouch et al [9,11]. This highlights the fact that the overlooked vascular compartment in both ISN/RPS grading systems for categorization of LN into various classes and activity and chronicity indices needs further modifications to include VL.…”
Section: Discussionsupporting
confidence: 85%
“…54 Lupus nephritis with renal thrombotic microangiopathy (TMA) responds to therapy similarly to those without TMA. 55 While immunosuppression is not in SRC treatment algorithms, if indicated for concurrent inflammatory skin, lung, or muscle (including myocardial) disease, these agents should be considered. This highlights the value of systematic cardiovascular studies in SSc-SLE overlap patients with systemic HTN.…”
Section: Potential Role For Renal Biopsymentioning
confidence: 99%